|
|
|
|
|
|
|
||
© The Rockefeller University Press,
0021-9525/1997//939 $5.00
The Journal of Cell Biology, Volume 137, Number 4,
, 1997 939-952
Article |
Carcinoembryonic Antigen, a Human Tumor Marker, Cooperates with Myc and Bcl-2 in Cellular Transformation
Department of Medical Biophysics, University of Toronto, Ontario Cancer Institute, Toronto, Ontario, Canada M5G 2M9
Carcinoembryonic antigen (CEA) is a tumor marker that is overexpressed in many human cancers and functions in vitro as a homotypic intercellular adhesion molecule. We have investigated the possibility of synergy between CEA, v-Myc, and Bcl-2 in the transformation of cells with differentiation capacity. We find that v-Myc increases the cell division rate and maximum density of rat L6 myoblasts but also markedly stimulates both apoptosis and surprisingly, differentiation, thus preventing transformation. The superposition of Bcl-2 blocks the apoptotic stimulation of v-Myc and independently promotes further cell division at confluence, but still allows differentiation. The further expression of CEA has a dominant effect in blocking differentiation, regardless of the presence of the other activated oncogenes, generating cells that enter a reversible quiescent G0-like state in medium promoting differentiation. Transfectants expressing CEA with or without v-myc and bcl-2 allow the emergence of cells with the property of heritable, efficient, anchorageindependent growth in soft agar and the ability to markedly reduce the latency for tumor formation in nude mice. We propose that by prolonging cell survival in the presence of differentiation signals, CEA represents a novel class of dominant differentiation-blocking oncogene.
Malignant transformation is believed to require four critical events: acquisition of increased proliferative activity, abrogation of apoptosis, immortalization, and deletion of access to differentiation programs. Differentiation has generally been assumed to be attenuated by an increase in proliferative behavior, if only because these cellular programs are considered mutually inhibiting. A major focus of oncobiology, therefore, has been to identify and characterize genes that influence cellular proliferation and recently, genes that govern cell death. Prototypic members of these two classes of oncogenes are, respectively, c-myc (for reviews see Evan and Littlewood, 1993; Evan et al., 1994) and bcl-2 (for reviews see Korsmeyer, 1992; 1995).
c-myc is an early response gene implicated in emergence from quiescence and normal progression through the cell cycle, in the establishment and propagation of neoplasia and, paradoxically, in initiating apoptosis (for review see Evan and Littlewood, 1993; Packham and Cleveland, 1995). Cellular transformation induced by c-myc deregulation is, however, often incomplete and depends on the activation of another oncogene, such as ras (Land et al., 1983; Adams et al., 1985). In contrast, forced bcl-2 expression promotes cell survival both in vitro (Bissonnette et al., 1992; Fanidi et al., 1992) and in vivo (McDonnell et al., 1989; McDonnell and Korsmeyer, 1991) by preventing apoptosis. Cultured fibroblasts coexpressing myc and bcl-2 continue to proliferate at low mitogen concentrations and experience reduced cell death but are not morphologically transformed (Fanidi et al., 1992). Mice expressing both Eµ-myc and Eµ–bcl-2 transgenes (Strasser et al., 1990) accumulate cycling pre-B and differentiated B cells, display an increased frequency of monoclonal tumors, and die earlier than Eµ-myc mice (Adams et al., 1985), observations that are attributed to a tumorigenic cooperativity between Myc and Bcl-2. The latent period and monoclonal nature of the tumors suggest, however, that additional mutations are required. Thus, Myc and Bcl-2 together result in the expansion of a population of benign cells that retain, at least in part, the capacity for differentiation.
Our laboratory has used a well characterized in vitro differentiation system, the immortal rat L6 skeletal myoblast cell line (Yaffe, 1968), to investigate oncogene action in the context of aberrant expression of human carcinoembryonic antigen (CEA).1 First discovered to be overexpressed in human colon tumors (Gold and Freedman, 1965), CEA has since been widely used as a marker in the clinical management of many cancers, including carcinomas of the colon, breast, and lung (Averbach and Sugarbaker, 1995). CEA is a glycophosphatidylinositol-linked (Hefta et al., 1988; Takami et al., 1988) cell surface glycoprotein of the immunoglobulin gene superfamily that has been shown to mediate homotypic intercellular adhesion (Benchimol et al., 1989; Oikawa et al., 1989).
We have proposed a model in which overproduction of CEA plays an active role in carcinogenesis by disrupting the normal tissue architecture of colonic epithelium, leading to inhibition of differentiation and tissue dysplasia (Benchimol et al., 1989). We contend that overproduction and redistribution of CEA from apical to the lateral and basal surfaces of colonic crypt epithelial cells perturbs normal intercellular interactions leading to the adoption of a multilayered ("stratified") epithelial configuration, perhaps mimicking the multilayered configuration seen in embryonic colonic epithelium. The predicted effect of this distortion in tissue architecture is the inhibition of normal colonocyte terminal differentiation, thus potentiating increased cell division. In support of this model we have recently shown that the cell surface levels of CEA determined by cytofluorometric analysis of highly purified epithelial colonocytes from freshly excised colon carcinomas and adjacent normal tissue are elevated in the tumor cells and at levels that are inversely correlated with the degree of differentiation of the tumors (Ilantzis et al., 1997).
To test the proposed differentiation-inhibiting effect of CEA directly in a well defined differentiation system, rat L6 myoblasts were used. In low serum, L6 cells withdraw irreversibly from the cell cycle, align, and form multinucleated myotubes while concomitantly upregulating musclespecific gene products (Nadal-Ginard, 1978). Myogenesis of L6 cells requires a complex series of cell–cell recognition and membrane fusion events that are mediated by a number of adhesion systems (Knudsen, 1990) and the upregulation of functional Myf5 and myogenin, members of the MyoD family of skeletal muscle transcriptional regulators (for review see Olson and Klein, 1994). Ectopic expression of cell surface CEA blocks biochemical and morphological myogenic differentiation in L6 myoblasts (Eidelman et al., 1993); since the CEA-imposed differentiation block can be released by peptides representing the two adhesion domains of CEA, the effect depends on CEA–CEA interactions (Eidelman et al., 1993; Zhou et al., 1993). We hypothesized that L6 cells stably expressing CEA, which retain their viability and proliferative potential while remaining in a quiescent nondifferentiated state for weeks in differentiation medium (Eidelman et al., 1993; Screaton, R.A., and C.P. Stanners, unpublished observations), should show increased susceptibilty to further malignant progression induced by oncogenic activation. To directly test this idea we have examined cellular phenotypes in single and multiple transfectants of the rat L6 and mouse C2 (Yaffe and Saxel, 1977) myoblast cell lines to examine possible synergism between Myc, Bcl-2, and CEA in transformation.
Extensive evidence has led to the prevailing view that activation of the cellular proliferative machinery results in the obligatory disruption of the myogenic differentiation program, which is normally accessed after arrest in the G1 phase of the cell cycle. Specifically, myogenesis can be prevented by maintaining cells in high concentrations of soluble growth factors such as PDGF and IGF-I (Screaton, R.A., and C.P. Stanners, unpublished) and by the forced expression of cellular or viral oncogenes (for review see Alema and Tato, 1994), including c-myc (Denis et al., 1987; La Rocca et al., 1994) and v-myc (La Rocca et al., 1989). The mechanism of disruption has been suggested to involve either the stimulation of proliferative behavior, which precludes cell cycle withdrawal, or the direct inactivation of Myf5 (Braun et al., 1992). We present data showing that v-myc expression in L6 cells increases the division rate and saturation density, promotes cell death by apoptosis in limiting serum, and contrary to previous reports, accelerates myogenic differentiation. Superimposed expression of bcl-2 relieves cell loss due to apoptosis and independently promotes further cell division at confluence but does not prevent differentiation. In low serum, CEA induces a reversible quiescent G0-like state that is incompatible with progression to terminal differentiation. We demonstrate that cells expressing CEA in addition to v-myc and bcl-2 proliferate faster, reach higher saturation densities, neither undergoes apoptosis nor differentiates in low serum, and furthermore, are capable of giving rise to large anchorage-independent colonies that form tumors in nude mice. CEA is the critical factor in allowing the emergence of these colonies and in reducing the latent period of tumor formation. These results suggest that CEA may contribute to malignancy in myoblasts by interfering exclusively with access to the differentiation program, inducing reversible quiescence in the presence of differentiation stimuli and increased susceptibility to proliferative oncogene activation.
 |
Materials and Methods |
|---|
 TopAbstract Materials and Methods ResultsDiscussionReferences |
|---|
Infections
L6 cells were incubated with replication-defective recombinant retrovirus containing either pBabe(avian v-myc)hygro (Facchini et al., 1994), pBabe(human bcl-2)puro (Zhu et al., 1996), or the vector alone controls (Morgenstern and Land, 1990) in 2.5 ml 
-MEM plus 10% FBS supplemented with 8 µg/ml polybrene for 2 h at 37°C. Cells were then washed and incubated with GM overnight. The cultures were subcultured 1:5 to 1:20 and selection started 24 h later with GM containing hygromycin B (v-myc) or puromycin (bcl-2) at 100 µg/ml and 2 µg/ml, respectively. After 7 d of selection, selective drugs (hygromycin or puromycin) were removed, and total populations of resistant clones were pooled and cultured thereafter without selection. v-Myc and Bcl-2 expression was verified by immunoblotting. Total populations were used to avoid the possibility of clonal variation in cellular properties unrelated to the phenotypic effects of the gene being tested. Proof of the polyclonality of these populations was provided by the presence of multiple integration sites in genomic DNA from the appropriate cell populations as revealed by Southern analysis using cDNA-specific probes for v-myc and bcl-2 (not shown). Cultures used for experiments were obtained from frozen stocks incubated for relatively few doubling times. The observed effects on cellular phenotype were reproduced with distinct total populations generated by repeating the infections for v-myc and bcl-2. No loss of v-Myc and Bcl-2 was noted during the course of the experiments (not shown). A triple selection with G418 (for CEA, see below), hygromycin, and puromycin done in separate steps allowed for the isolation of a population of cells expressing CEA, v-myc, and bcl-2.
Transfections
L6 or C2 myoblasts were seeded at 2 x 105 cells/100-mm dish and cotransfected 24 h later by calcium phosphate coprecipitation with 5 µg of p91023B expression vector (courtesy of Kaufman, R., Genetics Institute, Boston, MA) or PKJ expression vector containing full-length CEA cDNA (clone 17; Beauchemin et al., 1987) and 0.5 µg pSV2neo plasmid per dish. Neomycin (G418)-resistant total transfectant populations were selected with 400 µg/ml G418 for 10–14 d. G418-resistant clones were pooled and sorted for high surface CEA levels by FACS using polyclonal rabbit anti– human CEA antibody. To enrich for stable CEA-producing cells, sorted populations were cultured without G418 selection for 
20 doubling times, resorted for residual high CEA producers, and subsequently maintained in GM containing G418. Proof of polyclonality was provided by Southern analysis of genomic DNA using a CEA cDNA probe: pooled, sorted, and stabilized populations showed numerous integration sites and distinct patterns when using both CEA and neo specific probes in three out of the five independent clones isolated from the final sorted L6C population (not shown). Transfectant clone L6(CEA-1) was generated previously and designated L6-17 (Eidelman et al., 1993). G418 was removed from growth media 24 h before the application of the various functional assays. No loss of surface expression of CEA was detected over the culture period required for the assays (not shown).
Differentiation Assays
To induce differentiation, L6 and C2 cells were seeded on day 0 at 7 x 103 and 3.5 x 103 cells/cm2, respectively, in 60-mm plastic tissue culture petri dishes in 4 ml DME plus 10% FBS. On day 3, when cells were nearly confluent, the medium was changed to DME containing 2% horse serum (differentiation medium [DM]). Cells were assessed for differentiation/fusion on day 7 unless otherwise noted. Fusion index was determined as described previously (Eidelman et al., 1993). To investigate proliferation and differentiation capabilities of cells in medium containing low serum, cells were seeded on day 0 directly in DM at concentrations listed above and after 4 d incubation, fixed with 2.5% glutaraldehyde in PBS, and stained with hematoxylin. As a further assay of differentiation, cells were seeded in GM at 200 cells/60-mm petri dish, incubated for 10 d without a change of medium, as described for the viability assay, and then stained as above. The percentage of colonies with fused cells in their nonproliferating centers was then determined. For anti-myosin immunofluorescent staining, cultures were induced to differentiate in multiwell chamber slides (Nunclon®; Nunc, Inc., Naperville, IL) and prepared as described (De Giovanni et al., 1993).
Cell Lysis and Immunoblotting
Cells at a concentration of 107/ml were boiled in SDS lysis buffer (100 mM Tris, pH 8.0, 10% glycerol, 2% SDS) for 5 min and clarified by centrifugation. Protein determinations were made using BCA reagent (Pierce, Rockford, IL). 50–100 µg total protein was resolved by SDS-PAGE and transferred electrophoretically to a 0.45 µm PVDF membrane (Millipore Corp., Bedford, MA). Membranes were incubated with polyclonal panMyc antibody (generously provided by Evan, G.I., Imperial Cancer Research Fund, London, UK) at a dilution of 1:1,000 or polyclonal anti–Bcl-2 antibody (kind gift of Andrews, D., McMaster University, ON, Canada) at a dilution of 1:5,000 for 1 h at 25°C in TBST/M (25 mM Tris, pH 8.0, 62.5 mM NaCl, 0.4% Tween, 10% milk). After extensive washing, membranes were developed with HRP-conjugated anti–rabbit antibody and visualized by ECL reagent (Amersham Life Science, Pittsburgh, PA), which was used according to manufacturer's instructions.
Growth Curves
2 x 104 L6 cells were seeded in 60-mm dishes in GM. Triplicate cultures were rendered single cell suspensions by trypsinization every 24 h and their cell numbers individually determined using a particle counter (Coulter Electronics Inc., Hialeah, FL). Plates were not refed fresh medium during the course of the experiment. Cell size distributions were obtained using a channelyzer (Coulter Electronics Inc.), and their mean values were determined. All distributions were essentially symmetrical such that mean and mode values were equivalent.
Cell Viability Assay
200 cells (or nuclei equivalent, where cell fusion was appreciable) were seeded in GM in replicate 60-mm dishes and incubated at 37°C for 9–10 d. The resultant colonies were rinsed with PBS, fixed with 3.7% formaldehyde in PBS, and stained with 0.1% methylene blue. The number of colonies of >25 cells was determined by eye and expressed as a percentage of the number of cells seeded to give the plating efficiency.
Colony Formation in Soft Agar
103 cells were seeded in 60-mm dishes in 0.3% agar in 5 ml GM on a bottom layer of 0.5% agar in 3 ml GM and incubated at 37°C. Plates were not refed during the course of the experiment. Uniform, dense colonies of >100 or >500 cells were counted by microscopic observation 3–4 wk after seeding, as indicated.
Chromatin Staining and Apoptotic Frequency Determination
Cells were seeded for differentiation in 60-mm dishes in GM. The culture medium was changed to DM on day 2 and incubated for an additional 24 h, at which time the cultures were trypsinized and the resultant cell suspension pooled with nonadherent cells in the medium and centrifuged. Cell pellets were resuspended in 1 ml DME, and an equal volume of ice-cold fixative (3:1 ratio of 95% EtOH to glacial acetic acid) was added dropwise with intermittent vortexing. Cells were collected by centrifugation, resuspended in 1 ml of fixative, and incubated on ice for 10 min. Fixed cells were centrifuged, resuspended in 200 µl fixative, mounted on cold slides, and quick dried over a boiling water bath. Slides were immersed in a saturated solution of orcein in 50% glacial acetic acid for 30–60 min at 25°C. Damaged cells with condensed chromatin, confirmed by electron microscopy to be apoptotic, were easily distinguished; their numbers relative to undamaged cells were determined in six separate fields. A minimum of 300 cells was counted per field.
Transmission Electron Microscopy
Cells were incubated in DM for 24 h, as described above for chromatin staining, before fixation in 2.5% glutaraldehyde and processed for electron microscopy using standard procedures. Cells were viewed under an electron microscope (Philips Electronic Instruments, Inc., Mahwah, NJ).
FACS Analysis
Cultures were trypsinized and resuspended in ice cold PBS plus 2% FBS (PBSF). 2.5 x 105 cells were incubated with polyclonal rabbit or goat antiCEA antibodies diluted 1:100 (rabbit) or 1:600 (goat) in a total volume of 0.5 ml PBSF for 30 min on ice. Cells were centrifuged, rinsed with 2 ml PBSF, and resuspended in 0.5 ml PBSF containing FITC-conjugated rabbit anti–goat or goat anti–rabbit antibody diluted 1:100. After 30 min incubation on ice, cells were rinsed and resuspended in 0.75 ml PBSF for cytofluorometric analysis (FACScan®; Becton Dickinson, Bedford, MA).
Tumorigenicity Assay
To assay for tumorigenicity, 8–9 wk old nude mice (Swiss nu/nu; Taconic Farms Inc., Germantown, NY) were injected intramuscularly in both hind legs with cells resuspended in 100 µl serum-free PBS. The average latent periods for tumor formation by 105 and 3 x 105 injected cells (or 5 x 105 cells in the case of M alone) were determined as the time of appearance of a visible mass (>0.5 cm in diameter) at the site of injection or, for cases in which tumors developed inside the leg, the time of visible swelling of the leg and/or an alteration in gait. Differences in tumor latency were evaluated using the Student's t test.
Tumor Resection and Dissociation
Freshly excised tumor tissue was rinsed well with cold PBS, finely minced, and incubated in a sterile-filtered solution containing 50 U/ml purified collagenase (CLSPA) and 0.13% CLS-2 collagenase (Worthington Biochem. Corp., Freehold, NJ) in PBS supplemented with 10 µg/ml DNAseI for 30– 45 min at 37°C. After washing with GM to stop the dissociation, cells were filtered through a 70-µm filter and collected by centrifugation. Cells were seeded in GM containing 50 µg/ml gentamycin. 24–36 h later, cultures were divided by trypsinization and introduced into selective media containing either G418 (CEA+ lines) or puromycin (Bcl-2+ lines). After 3 d growth under selection, these tumor lines (denoted t) were expanded and then reintroduced into soft agar and nude mice.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
|
|
|
|
|
|
|
|
CEA Blocks Differentiation and Maintains Proliferative Potential of L6 and C2 Myoblasts
To affect complete transformation of L6 myoblasts by Myc and Bcl-2, a gene product that could block myogenic differentiation was required. We previously reported that CEA could provide a complete block of both morphological and biochemical myogenic differentiation of L6 cells while leaving the cells with proliferative potential (Eidelman et al., 1993). We decided first to characterize the cell biology of CEA-expressing L6 cells, to check for the generality of the phenomenon in another myogenic cell line, and finally to superimpose CEA on MB cells to determine whether this combination of genes would result in full malignant transformation. To this end, L6 rat and C2 mouse myoblasts were transfected with expression vectors containing CEA cDNA (Beauchemin et al., 1987) by calcium phosphate precipitation. Stable transfectant L6 and C2 total cell populations were enriched for cell surface CEA by cytofluorometric sorting after labeling with anti–human CEA antibody. These total transfectant populations (L6C or C, C2C) and individual clones (L6C-1) were analyzed for CEA expression by FACS analysis (Fig. 7, A and C). The levels of cell surface expression of CEA were within the range seen by FACS analysis of purified colonocytes from freshly excised human colon carcinomas (Ilantzis et al., 1997).
|
CEA Induces a Reversible G0 Arrest in DM
To determine the characteristics of the cell cycle arrest effected by CEA, cells from L6C-1 cultures incubated for increasing time in DM were harvested, stained with propidium iodide, and their nuclear DNA content analyzed by cytofluorometric analysis. Fig. 8 shows that the L6C-1 cells arrested exclusively with a postmitotic, preDNA synthetic G1 DNA content. Furthermore, upon addition of FBS (20%) or PDGF-BB (not shown) to these cells on day 9 in DM, DNA replication was reinitiated with a lag of 18 h (Fig. 8). The length of the 18 h lag period was unchanged after an additional 7 d (not shown), suggesting that L6C-1 cells reach a quiescent state after 9 d that does not deepen with increasing time in DM. The length of a normal G1 phase was calculated from FACS profiles of DNA content of exponentially growing L6C-1 cells, by determining the percentage of cells in either G1, S, or G2/M (Stanners and Till, 1960), giving a value of 9.6–10.0 h. A lag of 18 h therefore represents an 8 h prolongation of the normal G1 period and suggests that L6C-1 cells enter a G0-like quiescent state on or before day 9 in DM. Thus CEA expression appears to induce cells to enter a viable, reversible G0-like quiescent state that is incompatible with differentiation and permanent cell cycle withdrawal. Such a state should be susceptible to oncogenic activation.
|
When CEA expression was superimposed on MB cells (MBC), the doubling time was shorter and typical of M cells (Fig. 2, inset), confirming the overriding effect of v-Myc. The effect of Bcl-2 to annul the v-Myc–induced increase in apoptosis was also preserved (Fig. 6 B, compare MB and MBC), as was the ability of both Bcl-2 and CEA to increase saturation density (Fig. 2, inset). However, CEA profoundly modified the effects of v-Myc in confluent serum-limited conditions by blocking the enhanced differentiation phenotype (Fig. 5). In the growth (Fig. 2), colony (Fig. 4), and low serum (Fig. 5) assays, the presence of CEA in every population of transfectants, regardless of the presence of v-Myc and/or Bcl-2, completely prevented differentiation as measured by the appearance of multinucleated and/or myosin-positive cells. Thus the Myc, Bcl-2, and CEA combination seemed to endow L6 cells with the requisite attributes for full transformation. We tested this supposition directly using soft agar and tumorigenicity assays.
Effect on Transformation.
CEA expression neither conferred anchorage independence upon L6 cells when expressed alone nor interfered with the low-level soft agar colony formation induced by v-Myc (Table I). However, MBC cells produced rare macrocolonies (>500 cells) in soft agar which did not form in MB plates. These MBC macrocolonies (MBC-m), when rendered single cells and reintroduced into soft agar, bred true with an efficiency for colony formation ranging from 7 to 78% (Table I, and data not shown). It seemed possible that the macrocolonies could represent a minority of the MBC population with a particular set of heritable expression levels for the three transfected gene products that allowed rapid growth in soft agar and tumorigenicity in nude mice. Whereas this hypothesis is impossible to rule out completely, we consider it unlikely since, for CEA at least, nonheritable variation in expression levels in individual cells exceeds by far any heritable variability we have been able to reveal by cloning or FACS sorting. Furthermore, MBC-m and tumor-derived cell lines did not show an increase in the levels of expression of v-Myc and Bcl-2 by immunoblot analysis (data not shown). Thus we suggest that MBC-m cells represent members of the population with additional inherited changes endowing them with the ability to grow more efficiently when deprived of anchorage. Interestingly, very rare macrocolonies were also observed on plates seeded with cells other than MBC but only with C, BC, or MC cells, i.e., cells expressing CEA, regardless of the other genes expressed. These macrocolonies, when picked and replated, also bred true (Table I), indicating again the presence of further heritable transforming lesions. The expression of CEA thus greatly facilitates the emergence of cells bearing such lesions.
Effect on Tumorigenicity.
Tumorigenicity was assessed by injection of cells into the thigh muscles of nude mice (Fig. 9). Interestingly, shorter latent periods were seen for all cell types expressing CEA (Fig. 9, compare P with C, B with BC, and MB with MBC), indicating that the presence of CEA favors a more rapid emergence of malignant cells. In fact, the presence of CEA alone was capable of reducing the tumor latent period by 50%. This effect was highly statistically significant (P < 0.0005 for P vs. C, n = 6; P < 0.01 for B vs. BC, n = 6; P < 0.0005 for MB vs. MBC, n = 8) and agrees with the observation that soft agar macrocolonies were observed only for cell lines expressing CEA, as noted above. The tumors were examined for their gross morphology and microscopic histology. Cell lines capable of differentiation in vitro retained this property in the tumors they formed (Ordonez, C., R.A. Screaton, and C.P. Stanners, unpublished results). Tumors produced by C and BC cells appeared within 8 wk but grew slowly and were contained within the leg muscle (not shown); each consisted of an amorphous mass of nondifferentiated cells. MB, MBC, and MBC-m tumors migrated out of the site of injection to the muscle surface (not shown), indicating a more aggressive phenotype associated with v-Myc.
The question arose whether the tumors, especially those with extended latent periods, were composed of cells that possessed additional genetic lesions selected for during the growth period in vivo. To test for this, isolated tumors were rendered suspensions of single cells by collagenase treatment and evaluated for their resistance to the cytotoxic agent(s) used to isolate the original transfectants. A high percentage of the cells derived from tumors demonstrated resistance with the expected specificity. The drug resistant cells were subsequently tested for anchorage independence of growth. Nearly all, except for those produced by MBC-m cells, showed an increase in plating efficiency for colonies and macrocolonies in soft agar (Table I), implicating selection for preexisting or additional genetic changes during tumor growth. Finally, there is the question whether the MBC-m clones picked from soft agar themselves exhibited maximum tumorigenicity. Both drug resistant cells selected from excised MBC-m tumors and the original MBC-m cells used to produce them were reinjected intramuscularly into nude mice. A small but statistically insignificant decrease in latency was observed for the tumor-derived cells (not shown). When tested for growth characteristics in GM, a progressive increase in saturation density (MBC-m-t > MBC-m > MBC) was noted, indicating a step-wise evolution of the transformed phenotype (not shown).
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
The Role of Myc
Deregulated expression of the c-myc gene has been implicated in many types of human cancer (Spencer and Groudine, 1991), and this, in addition to the observed mitogeninduced changes in c-myc expression (Kelly et al., 1983) and the requirement for c-myc for the G1–S transition, strongly supports the model that this transcriptional regulator is central to the control of cellular proliferation. When v-myc, whose phenotypic and molecular effects have been found to mimic c-myc (Penn et al., 1990), was expressed in proliferating L6 cells, a reproducible decrease in the cellular doubling time and a higher maximum cell density were noted. Although the observed decrease in doubling time was relatively small, it would quickly result in the elimination of P cells in an exponentially increasing mixed population of P and M cells. These effects could be due to a more efficient use of serum growth factors by v-myc–expressing cells than the parental cells, allowing for more rapid cell growth, further cell division beyond normal saturation, and the production of smaller cells (Figs. 2 and 3).
Two additional cellular responses were also greatly stimulated by v-myc: apoptosis and myogenic differentiation. These anti-transforming effects were apparent when growth factors became limiting and were presumably responsible for the failure of M cells to form colonies efficiently in soft agar or to reduce the latency of tumor formation. The commonly observed effect of c-myc triggering apoptosis (Bissonnette et al., 1992; Evan et al., 1992; Fanidi et al., 1992; Hermeking and Eick, 1994; Wagner et al., 1994) is thus duplicated with v-myc in this system. Inhibition of myogenic differentiation at the morphological (Falcone et al., 1985; Crescenzi et al., 1994; La Rocca et al., 1994) or biochemical (Falcone et al., 1985; Denis et al., 1987; La Rocca et al., 1994) level by Myc, however, has been reported by most observers under differentiation conditions. Thus, our observation of a dramatic stimulation of differentiation appears to be unique. We feel that these differences with our findings could be due to systemdependent differences in the balance between Myc-induced apoptosis and differentiation, which both require reduced growth factor concentrations for execution. Our results are not due to a coincidence of myotube formation in a subpopulation of M cells that escaped apoptosis, since the M population formed colonies with high efficiency in GM, and 75% of these showed differentiation. This represented a very significant stimulation of differentiation relative to the parental cells, which showed 0% differentiated colonies under the same conditions (Fig. 4).
The Role of Bcl-2
The superposition of bcl-2 expression on L6 cells producing v-Myc had no effect on the acceleration of cell division induced by v-Myc (Fig. 2, inset) but completely suppressed apoptosis (Fig. 6 C). This is consistent with results from other systems, as overexpression of c-myc in cultured fibroblasts can induce both accelerated proliferation and apoptosis (Evan et al., 1992), with the latter being delayed by coexpression of bcl-2 (Bissonnette et al., 1992; Fanidi et al., 1992; Wagner et al., 1993). Our results further indicate a transforming activity of Bcl-2 in addition to its ability to inhibit apoptosis. L6 cells expressing bcl-2 alone reach higher saturation densities than the parental line (Fig. 2, inset), independent of any effect on cell death (Fig. 6 B). In the colony assay, MB colonies on average were twice the size of M colonies (not shown). In addition, cultures of L6 cells expressing bcl-2, regardless of the other oncogenes present, remained viable for prolonged culture periods without medium change (Fig. 2). This evidence, together with the growth characteristics of these lines (Fig. 2), suggests that Bcl-2 lowers the serum requirement for further cell division at normal saturation and, in v-Myc+ cells, blocks apoptosis allowing for their overgrowth in increasingly limiting serum. Positive effects of bcl-2 expression on cell growth parameters have been previously reported for 3T3 fibroblasts (Reed et al., 1991) and pro-B cells (Miyazaki et al., 1995). Interestingly, the Bcl-2–mediated block of apoptosis coincided with a failure to rapidly acidify the culture medium (Table II). The role of medium acidification in v-Myc–induced apoptosis in L6 cells is currently under investigation.
B cell directed expression of c-myc and bcl-2 together in transgenic mice resulted in the formation of monoclonal tumors (Strasser et al., 1990). By contrast, L6 cells expressing both v-myc and bcl-2 were not fully transformed, as they were unable to form normal-sized colonies in soft agar and did not give rise to any larger macrocolonies (Table I). We attribute this failure to the persistence of differentiation, thus abrogating the emergence of variants with more transformed properties. When tested in vivo, a significant but relatively small reduction in tumor latent period by MB cells was noted relative to M or B cells, though MB tumors were found to contain many differentiated cells (Fig. 9, and Ordonez, C., R.A. Screaton, and C.P. Stanners, unpublished observations).
The Role of CEA
We have shown previously that ectopic cell surface CEA expression by L6 myoblasts blocks entry to the myogenic differentiation program at a very early stage, i.e., before the upregulation of the myogenic transcriptional regulator, myogenin (Eidelman et al., 1993). Cells expressing CEA alone were slowed in their division rate and reached lower initial saturation densities (Fig. 2). In cells producing both CEA and v-Myc, v-Myc was dominant in accelerating cell proliferation but succumbed to the effects of CEA at confluence. We suggest that these effects of CEA are due to an increase in the probability in DM of cells entering a G0-like state from the G1 period of the cell cycle (Figs. 7 and 8). Since the parental cells tend to differentiate under these conditions, it is difficult to determine whether this state is entirely novel or a state transiently traversed by the parental cells during their passage to differentiation. CEA was confirmed to block differentiation in this study and was dominant over the differentiation stimulating effect of v-Myc in MC cells, blocking differentiation completely.
Cells expressing v-myc, bcl-2, and CEA together possessed all of the properties expected to yield a fully transformed phenotype: a higher division rate, a higher saturation density, reduced apoptosis, no differentiation, and long term survival (Figs. 2 and 4–6) yet did not produce colonies in soft agar with high efficiency (Table I). MBC cell populations did, however, contain cells at low frequency capable of producing very large anchorage independent macrocolonies which, when picked and dispersed, bred true, forming macrocolonies with high efficiency (Table I). Interestingly, macrocolonies were found in all cell cultures in which CEA was expressed: MBC, MC, BC, and even C cell populations (Table I). These variants also seemed to be responsible for the formation of tumors, since the latent periods for tumor formation were lowest for cell lines containing them (Fig. 9), the cells selected for during tumor growth were highly enriched for them (Table I), and pure populations of variant cells showed the lowest tumor latency.
"Fertile Soil" Hypothesis
From these results, we suggest that CEA expression accelerates progression towards transformation and increased tumorigenicity by blocking terminal differentiation, thus providing a "fertile soil" for the emergence of cellular variants with increased proliferative potential. Indeed, after reaching an initial stationary phase, all cell lines expressing CEA tend to increase slowly in cell number (Fig. 2), indicating an increased sensitivity to proliferative stimuli. CEA-expressing cell lines also accumulate tumorigenic macrocolony-producing cells, as noted above. The nature of the heritable changes giving rise to macrocolonies is presently unknown. Bcl-2 has also been suggested to provide a cellular state conducive to the emergence of more autonomous variants, yet accomplishes this by a fundamentally different mechanism, i.e., by the suppression of apoptosis. In transgenic mice, ectopic bcl-2 expression alone does not directly result in tumors (McDonnell et al., 1989) yet generates a population of quiescent cells that possesses oncogenic potential, perhaps as a consequence of extended survival (McDonnell and Korsmeyer, 1991). In the L6 system, however, Bcl-2 was relatively ineffective in promoting the emergence of variants or decreasing tumor latency. Thus CEA seems to posess a novel oncogenic activity, with a distinct mechanism from Bcl-2 for the induction of a long term viable quiescence (Fig. 10).
|
Perhaps the most relevant system for examining the effect of CEA is therefore the human colonic epithelium where CEA family members, CEA, nonspecific cross-reacting antigen, and biliary glycoprotein, undergo dramatic changes in expression during carcinogenesis (Cournoyer et al., 1988; Boucher et al., 1989; Hinoda et al., 1991; Neumaier et al., 1993). The technical complexity and poorly defined differentiation process of the colonic system, however, renders it less amenable to experimental investigation in vitro. The results presented in this work refer to a myoblast model system chosen for ease of experimentation and interpretation and with assumed relevance to systems where CEA is naturally expressed. The results, which support the above hypothesis, are not species or cell line specific in that the basic observation of the induction of a viable quiescent cellular state in which myogenic differentiation is blocked was extended to mouse C2 myoblasts (Fig. 7). We are currently investigating the effect of CEA expression on other differentiating systems.
The validity of the use of the myoblast system is supported by our recent observations that CEA and nonspecific cross-reacting antigen, both of which block myogenic differentiation (Eidelman et al., 1993; Rojas et al., 1996), are upregulated on the surface of purified colon carcinoma cells relative to normal colonocytes from the same patient and at levels inversely related to the degree of differentiation, while biliary glycoprotein, which has no effect on myogenic differentiation (Rojas et al., 1996), shows no increase in expression (Ilantzis et al., 1997). An upregulation of CEA was also observed in early dysplastic lesions of the colon (Ilantzis et al., 1997). Interestingly, both bcl-2 upregulation (Bedi et al., 1995; Bosari et al., 1995; Sinicrope et al., 1995) and myc overexpression (Guillem et al., 1995, and references therein) have been reported to be involved in a high proportion of human colon adenomas and carcinomas.
The effect of CEA on myogenesis is similar to that of oncogenic forms of H-ras and N-ras (Olson et al., 1987), as the block in differentiation is not dependent on aberrant proliferation. A major difference in the effects of CEA and ras, however, is the reduction in saturation density mediated by CEA (Fig. 2, inset), which precludes placing CEA and ras in the same category of oncogene. As the CEA effect is reversible by supplementing DM with peptides corresponding to the CEA adhesion domains (Eidelman et al., 1993), it is tempting to speculate that the CEA– CEA interaction may interfere directly with intracellular signaling events required for activation of the myogenic differentiation program. In fact, we have shown that CEA can signal through its GPI anchor to phosphorylate Src family kinases and other cellular proteins (Draber, P., unpublished observations) and that the GPI anchor is absolutely required for the inhibitory effect on myogenic differentiation (Screaton, R.A., and C.P. Stanners, unpublished observations).
CEA: A Dominant Differentiation-blocking Oncogene?
Can CEA be considered an oncogene? Often protooncogenes are found to comprise ubiquitous elements of the cell proliferation or differentiation machinery (Hunter, 1991; 1993). CEA does not have a known counterpart within the genomes of oncogenic viruses and does not possess overt transforming properties in cultured cells. Does CEA function as an inducer of quiescence in normal growth control of all cells? The restricted expression pattern of CEA makes this unlikely. However, CEA could be used as an explicit (as opposed to ligand controlled) differentiation block during embryonic development, in situations where cells are required to remain associated in undifferentiated collectives. We suggest that inappropriate expression of CEA in adult life in cells with both proliferation and differentiation capacity promotes survival in the presence of differentiation stimuli, thus facilitating the acquisition of progressive mutations. We therefore propose that CEA defines a new class of gene with dominant, differentiation-blocking oncogenic activity.
|
Acknowledgments |
|---|
This work was supported by grants from the National Cancer Institute of Canada and the Medical Research Council of Canada to C.P. Stanners and from the Medical Research Council of Canada to L.Z. Penn. R.A. Screaton was supported by a Studentship from the Research Institute of the Royal Victoria Hospital, Montreal, Canada.
Submitted: 19 July 1996
Revised: 13 December 1996
1. Abbreviations used in this paper: CEA, carcinoembryonic antigen; DM, differentiation medium; GM, growth medium.
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmitter RD & Brinster RL. The c-myconcogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice, Nature (Lond), 1985, 318, 533–538.[Medline]
Ahnen DJ, Kinoshita K, Nakane PK & Brown WR. Differential expression of carcinoembryonic antigen and secretory component during colonic epithelial cell differentiation and in colonic carcinomas, Gastroenterology, 1987, 93, 1330–1339.[Medline]
Alema S & Tato F. Oncogenes and muscle differentiation: multiple mechanisms of interference, Semin Cancer Biol, 1994, 5, 147–156.[Medline]
Averbach, A.M., and P.H. Sugarbaker. 1995. Use of Tumor Markers and Radiologic Tests in Follow-up. In Cancer of the Colon, Rectum and Anus. A.M. Cohen and S.J. Winawer, editors. McGraw-Hill, New York. 725–751.
Beauchemin N, Benchimol S, Cournoyer D, Fuks A & Stanners CP. Isolation and characterization of full-length functional cDNA clones for human carcinoembryonic antigen, Mol Cell Biol, 1987, 7, 3221–3230.
Bedi A, Pasricha P, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, Zehnbauer BA, Hamilton SR & Jones RJ. Inhibition of apoptosis during development of colorectal cancer, Cancer Res, 1995, 55, 1811–1816.
Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K & Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule, Cell, 1989, 57, 327–334.[Medline]
Bissonnette RP, Echeverri F, Mahboubi A & Green DR. Apoptotic cell death induced by c-myc is inhibited by Bcl2, Nature (Lond), 1992, 359, 552–554.[Medline]
Bosari S, Moneghini L, Graziani D, Lee AKC, Murray JJ, Coggi G & Viale G. bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas, Hum Pathol, 1995, 26, 534–540.[Medline]
Boucher D, Cournoyer D, Stanners CP & Fuks A. Studies on the control of gene expression of the carcinoembryonic antigen family in human tissue, Cancer Res, 1989, 49, 847–852.
Braun T, Bober E & Arnold HH. Inhibition of muscle differentiation by the adenovirus E1a protein: repression of the transcriptional activating function of the HLH protein Myf-5, Genes Dev, 1992, 5, 888–902.
Cournoyer D, Beauchemin N, Boucher D, Benchimol S, Fuks A & Stanners CP. Transcription of the genes of the carcinoembryonic antigen family in malignant and nonmalignant tissues, Cancer Res, 1988, 48, 3153–3157.
Crescenzi M, Crouch DH & Tato F. Transformation by myc prevents fusion but not biochemical differentiation of C2C12 myoblasts: mechanisms of phenotypic correction in mixed culture with normal cells, J Cell Biol, 1994, 125, 1137–1145.
De Giovanni C, Lollini PL, Dolcetti R, Landuzzi L, Nicoletti G, D'Andrea E, Scotland K & Nanni P. Uncoupling of growth inhibition and differentiation in dexamethasone-treated human rhabdomyosarcoma cells, Br J Cancer, 1993, 67, 674–679.[Medline]
Denis N, Blanc S, Leibotvitch MP, Nicolaiew N, Dautry F, Raymondjean M, Kruh J & Kitzis A. c-myc oncogene expression inhibits the initiation of myogenic differentiation, Exp Cell Res, 1987, 172, 212–217.[Medline]
Eidelman F, Fuks A, DeMarte L, Taheri M & Stanners CP. Human carcinoembryonic antigen, an intercellular adhesion molecule, blocks fusion and differentiation of rat myoblasts, J Cell Biol, 1993, 123, 467–475.
Evan GI & Littlewood TD. The role of c-myc in cell growth, Curr Opin Genet Dev, 1993, 3, 44–49.[Medline]
Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ & Hancock DC. Induction of apoptosis in fibroblasts by c-myc protein, Cell, 1992, 69, 119–128.[Medline]
Evan G, Harrington E, Fanidi A, Land H, Amati B & Bennett M. Integrated control of cell proliferation and cell death by the c-myc oncogene, Philos Trans R Soc Lond B Biol Sci, 1994, 345, 269–275.[Medline]
Facchini LM, Chen S & Penn LJZ. Dysfunction of the Mycinduced apoptosis mechanism accompanies c-mycactivation in the tumorigenic L929 cell line, Cell Growth Differ, 1994, 5, 637–646.[Abstract]
Falcone G, Tato F & Alema S. Distinctive effects of the viral oncogenes myc, erb, fps, and src on the differentiation program of quail myogenic cells, Proc Natl Acad Sci USA, 1985, 82, 426–430.
Fanidi A, Harrington E & Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes, Nature (Lond), 1992, 359, 554–556.[Medline]
Gold P & Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques, J Exp Med, 1965, 121, 439–462.[Abstract]
Guillem, J.G., P.B. Paty, and N. Rosen. 1995. Molecular Biology of Colorectal Cancer. In Cancer of the Colon, Rectum and Anus. A.M. Cohen and S.J. Winawer, editors. McGraw-Hill, New York. 149–156.
Hefta SA, Hefta LJF, Lee TD, Paxton RJ & Shively JE. Carcinoembryonic antigen is anchored to the membrane by covalent attachment to a glycophosphatidylinositol moiety: identification of the ethanolamine linkage site, Proc Natl Acad Sci USA, 1988, 85, 4648–4652.
Hermeking H & Eick D. Mediation of c-Myc apoptosis by p53, Science (Wash DC), 1994, 265, 2091–2093.
Hinoda Y, Takahashi H, Higashide T, Nakano T, Arimura Y, Yoshimoto M, Tsujisaki M, Imai K & Yachi A. Correlated expression of mRNAs of carcinoembryonic antigen and non-specific cross-reacting antigen genes in malignant and nonmalignant tissues of the colon, Jpn J Clin Oncol, 1991, 21, 75–81.
Hunter T. Cooperation between oncogenes, Cell, 1991, 64, 249–270.[Medline]
Hunter T. Oncogenes and cell proliferation, Curr Opin Genet Dev, 1993, 3, 1–4.
Ilantzis, C., S. Jothy, L.C. Alpert, P. Draber, and C.P. Stanners. 1997. Cell-surface levels of human carcinoembryonic antigen are inversely correlated with colonocyte differentiation in colon carcinogenesis. Lab. Invest. In press.
Jothy S, Yuan S-Y & Shirota K. Transcription of carcinoembryonic antigen in normal colon and colon carcinoma, Am J Pathol, 1993, 143, 250–257.[Abstract]
Kelly K, Cochran BH, Stiles CD & Leder P. Cell specific regulation of the c-mycgene by lymphocyte mitogens and platelet-derived growth factor, Cell, 1983, 35, 603–610.[Medline]
Knudsen KA. Cell adhesion molecules in myogenesis, Curr Opin Cell Biol, 1990, 2, 902–906.[Medline]
Korsmeyer S. Bcl-2 initiates a new category of oncogenes: regulators of cell death, Blood, 1992, 85, 879–886.[Medline]
Korsmeyer S. Regulators of cell death, Trends Genet, 1995, 11, 101–105.[Medline]
La Rocca, S.A., M. Grossi, G. Falcone, S. Alema, and F. Tato. Interaction with normal cells suppresses the transformed phenotype of v-myc-transformed quail muscle cells, Cell, 1989, 58, 123–131.[Medline]
La Rocca, S.A., D.H. Crouch, and D.A.F. Gillespie. c-Myc inhibits myogenic differentiation and myoD expression by a mechanism which can be dissociated from cell transformation, Oncogene, 1994, 9, 3499–3508.[Medline]
Land H, Parada LF & Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes, Nature (Lond), 1983, 304, 596–602.[Medline]
McDonnell TJ & Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18), Nature (Lond), 1991, 349, 254–256.[Medline]
McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP & Korsmeyer SJ. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation, Cell, 1989, 57, 79–88.[Medline]
Miyazaki T, Liu Z-J, Kawahara A, Minami Y, Yamada K, Tsujimoto Y, Barsoumian EL, Perlmutter RM & Taniguchi T. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation, Cell, 1995, 81, 223–231.[Medline]
Morgenstern JP & Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line, Nucleic Acids Res, 1990, 12, 3587–3596.
Murray, A., and T. Hunt. 1993. The Cell Cycle. Oxford University Press, Oxford, UK.
Nadal-Ginard B. Commitment, fusion, and biochemical differentiation of a myogenic cell line in the absence of DNA synthesis, Cell, 1978, 15, 855–864.[Medline]
Neumaier M, Paululat S, Chan A, Matthaes P & Wagener C. Biliary glycoprotein, a potential cell adhesion molecule, is down-regulated in colorectal carcinomas, Proc Natl Acad Sci USA, 1993, 90, 10744–10748.
Oikawa S, Inusuka C, Kuroki M, Matsuoka Y, Kosaki G & Nakazato H. Cell adhesion of non-specific cross-reacting antigen (NCA) and carcinoembryonic antigen (CEA) expressed on CHO cell surface: homophilic and heterophilic adhesion, Biochem Biophys Res Commun, 1989, 164, 39–45.[Medline]
Olson E & Klein WH. bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out, Genes Dev, 1994, 8, 1–8.
Olson EN, Spizz G & Tainsky MA. The oncogenic forms of N-ras or H-ras prevent skeletal myoblast differentiation, Mol Cell Biol, 1987, 7, 2104–2111.
Packham G & Cleveland JL. c-Myc and apoptosis, Biochim Biophys Acta, 1995, 1242, 11–28.[Medline]
Penn, L.J.Z., E.M. Laufer, and H. Land. 1990. C-Myc: Evidence for Multiple Regulatory Functions. In Seminars in Cancer Biology. N. Jones, editor. W.B. Saunders Co., London. 69–80.
Reed JC, Talwar HS, Cuddy M, Baffy G, Williamson J, Rapp UR & Fisher GJ. Mitochondrial protein p26 BCL2 reduces growth factor requirements of NIH3T3 fibroblasts, Exp Cell Res, 1991, 195, 277–283.[Medline]
Rojas M, DeMarte L, Screaton RA & Stanners CP. Radical differences in functions of closely related members of the human carcinoembryonic antigen gene family, Cell Growth Differ, 1996, 7, 655–662.[Abstract]
Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ & Levin B. bcl-2and p53 oncoprotein expression during colorectal tumorigenesis, Cancer Res, 1995, 55, 237–241.
Spencer CA & Groudine M. Control of c-myc regulation in normal and neoplastic cells, Adv Cancer Res, 1991, 56, 1–48.[Medline]
Stanners CP & Till JE. DNA synthesis in individual L-strain mouse cells, Biochim Biophys Acta, 1960, 37, 406–419.[Medline]
Strasser A, Harris AW, Bath ML & Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl–2. , Nature (Lond), 1990, 348, 331–333.[Medline]
Takami N, Misumi Y, Kuroki M, Matsuoka Y & Ikehara Y. Evidence for carboxyl-terminal processing and glycolipid-anchoring of human carcinoembryonic antigen, J Biol Chem, 1988, 263, 12716–12720.
Wagner AJ, Small MB & Hay N. Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2, Mol Cell Biol, 1993, 13, 2432–2440.
Wagner AJ, Kokontis JM & Hay N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21 Waf1/Cip1, Genes Dev, 1994, 8, 2817–2830.
Weinberg RA. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis, Cancer Res, 1989, 49, 3713–3721.
Yaffe D. Retention of differentiation potentialities during prolonged cultivation of myogenic cells, Proc Natl Acad Sci USA, 1968, 61, 477–483.
Yaffe D & Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle, Nature (Lond), 1977, 270, 725–727.[Medline]
Zhou H, Fuks A, Alcaraz G, Bolling TJ & Stanners CP. Homophilic adhesion between Ig superfamily carcinoembryonic antigen molecules involves double reciprocal bonds, J Cell Biol, 1993, 122, 951–960.
Zhu W, Cowie A, Wasfy GW, Penn LZ, Leber B & Andrews DW. Bcl-2 mutants with restricted sub-cellular location reveal spatially distinct pathways for apoptosis in different cell types, EMBO (Eur Mol Biol Organ) J, 1996, 15, 4130–4141.[Medline]
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
4% for all data points, i.e., smaller than the diameters of the symbols themselves. (Inset) Doubling times, initial and 15-d saturation densities, and viabilities of L6 cell transfectants were obtained from the data shown in Fig. 
